TIPS: Medicare Part D Administration and Management
7 Medicare Part D Administration Tips
for Plan Staff Who Cannot Afford Errors
for Plan Staff Who Cannot Afford Errors
Medicare Part D administration changed significantly in 2025. The $2,000 out-of-pocket cap under the Inflation Reduction Act, the Medicare Prescription Payment Plan (M3P), and higher LIS protections all created new operational requirements that plan staff must execute correctly on every member interaction. Getting Part D administration wrong costs members money, generates CMS compliance findings, and suppresses Star Ratings. These seven tips address the highest-risk operational areas for plan staff who manage Part D benefits day to day.
$2,000
Part D Out-of-Pocket Cap in 2025
The Inflation Reduction Act set the annual Part D out-of-pocket cap at $2,000 for 2025, down from $8,000 in 2024. All covered Part D drugs count toward the cap, including those obtained through formulary exceptions. Deductibles and copays count. Plan staff must understand how the cap is tracked and communicated to members who are approaching it. The cap rises to $2,100 in 2026.
Patient Advocate Foundation: Understanding the Part D Cap (2025)
50%+
of Part D Drugs Subject to Utilization Management
In 2024, PDPs and MA-PDs applied some form of utilization management, prior authorisation, step therapy, or quantity limits, to more than 50% of the drugs on their formularies. For plan staff handling Part D drug requests, most calls now involve a utilization management step. Knowing how to apply, explain, and process UM correctly is core to the job.
AARP Policy Book: Medicare Part D Prescription Drug Benefit (2025)
14.2M
Beneficiaries Receiving LIS (Extra Help) in 2023
An estimated 14.2 million Medicare beneficiaries received the Low-Income Subsidy (Extra Help) in 2023, approximately one in five Part D enrollees. LIS status fundamentally changes a member’s cost-sharing, formulary access, and enrollment rights. Every Part D plan staff member must be able to identify LIS status and apply the correct cost-sharing before quoting any drug cost to a member.
Congressional Research Service: Medicare Part D Prescription Drug Benefit (2025)
Quick Summary: 7 Medicare Part D Administration Tips
- Always check LIS status before quoting any Part D cost-sharing to a member
- Apply the $2,000 OOP cap correctly and explain the M3P payment plan option
- Execute the transition policy accurately for every new enrollee and LTC resident
- Process prior authorisation and step therapy requests within required timeframes
- Identify and refer eligible members for Medication Therapy Management (MTM)
- Explain the Explanation of Benefits (EOB) correctly when members call about it
- Communicate formulary changes to members accurately and on time
Medicare Part D Administration Tips: Full Guidance
Tip 1: Always Check LIS Status Before Quoting Any Part D Cost-Sharing
Why It Matters
LIS (Low-Income Subsidy, also called Extra Help) members pay dramatically less for their prescriptions than standard Part D members. A full LIS member may pay $0 to a few dollars per prescription where a standard member pays $50 or more. If a plan staff member quotes the standard cost-sharing to an LIS member, they are giving wrong information that may cause the member to not fill a needed prescription, file a complaint, or switch plans. Source: CRS: Medicare Part D (2025)
What To Do
Pull the member’s account before quoting any cost. Verify LIS level: full (Level 1/2) or partial (Level 3/4). Apply the correct cost-sharing table for their LIS level. If the member’s LIS status in your system shows “pending” or has recently changed, verify against the most current CMS LIS file before giving the member a cost figure. LIS status can change mid-year and must be applied as of the effective date, not the date you discover it.
Common Mistake
Quoting the standard formulary copay from memory without pulling the member record first. Staff who know the standard tier copays may give those figures automatically, which is correct for standard members and wrong for LIS members. The correct answer is always look it up first, every time.
Pro Tip
Build a LIS verification step into your call intake screen as a mandatory field that must be confirmed before the drug cost field can be populated. Representatives who see the LIS status before they look up the drug cost cannot accidentally apply the wrong cost-sharing. This is an IT configuration change that pays for itself in the first month of avoided complaints.
Tip 2: Apply the $2,000 OOP Cap Correctly and Explain the M3P Option
Why It Matters
The $2,000 annual Part D out-of-pocket cap took effect on January 1, 2025 under the Inflation Reduction Act, a reduction from $8,000 in 2024. All covered Part D drugs count toward the cap, including those obtained through formulary exceptions. Deductibles and copays count. Members who hit the cap stop paying cost-sharing for the rest of the calendar year. Plan staff who do not understand the cap will give members wrong information about how much they still owe. Source: Patient Advocate Foundation: Part D Cap (2025)
What To Do
Know the three things that count toward the $2,000 cap: the annual deductible, copayments, and coinsurance for covered drugs. Know what does not count: drugs not on the formulary that the member pays for out of pocket. When a member is approaching or has reached the cap, inform them they will pay $0 cost-sharing for covered drugs for the rest of the calendar year. Also inform members with high drug costs about the Medicare Prescription Payment Plan (M3P), which lets them spread their out-of-pocket costs across monthly instalments throughout the year rather than paying all at once at the pharmacy.
Common Mistake
Telling a member that a drug they paid for out of pocket (because it was not on the formulary) counts toward their $2,000 cap. It does not. Only covered Part D drugs count. If a member paid cash for a drug that their plan does not cover, that payment does not count toward the cap, even if the drug is a legitimate medical need. This distinction is a common source of member confusion and complaints.
Pro Tip
Proactively notify members when they are within $200 of their $2,000 cap so they can plan their pharmacy visits accordingly. A member who does not know they are close to the cap may delay a refill unnecessarily. Members who hit the cap and are not informed they owe $0 going forward may not fill prescriptions they actually need at no cost to them, a health outcome and Star Ratings issue simultaneously.
Tip 3: Execute the Transition Policy Accurately for Every New Enrollee and LTC Resident
Why It Matters
CMS requires Part D plans to have a transition policy that provides temporary coverage for non-formulary drugs when a new member is enrolled and cannot immediately switch to a formulary drug. Without the transition supply, a new member who relies on a drug not on the plan’s formulary could go without their medication from day one of coverage. For long-term care residents, the transition period is extended and the requirements are more protective. Transition policy errors are one of the most audited Part D compliance areas. Source: CMS Part D Transition Policy Requirements
What To Do
For new enrollees in the retail setting: provide a temporary 30-day supply of a non-formulary drug during the first 90 days of coverage, and send a written notice within 3 business days telling the member the drug is not on the formulary and explaining their options (formulary exception, switching to a formulary alternative, or paying out of pocket). For LTC residents: provide multiple 31-day supplies throughout the member’s entire stay, not just the first 90 days. Document every transition fill and every notice sent. Keep the documentation for CMS audit review.
Common Mistake
Applying the 90-day retail transition rule to LTC residents. LTC residents have ongoing transition protections for the duration of their stay, they are not limited to the first 90 days. Denying a transition supply to a LTC resident after day 90 on the grounds that the transition period has ended is a compliance violation. LTC residents must always be able to get a transition supply while they remain in the facility.
Pro Tip
Track transition fills by member and monitor which members received a transition supply but have not yet received a formulary exception decision or switched to a formulary alternative. These are members who will hit the end of their transition period without a long-term solution, the plan should proactively reach out to their prescribers to facilitate the formulary exception or therapeutic substitution before the transition period ends, not after the next fill is denied.
Tip 4: Process Prior Authorisation and Step Therapy Requests Within Required Timeframes
Why It Matters
With more than 50% of Part D formulary drugs subject to some form of utilisation management, prior authorisation processing is a high-volume daily operation for Part D plans. CMS requires standard coverage determination requests to be decided within 72 hours; expedited requests must be decided within 24 hours. Failure to meet these timelines is an auto-forward to the Independent Review Entity, which is also a CMS audit finding. Slow PA processing is the single most common driver of member access complaints in Part D.
What To Do
Track every PA request from receipt timestamp to decision timestamp. Standard: 72-hour decision clock from receipt. Expedited (when a physician certifies standard timeframe would seriously jeopardise health): 24-hour clock. If a standard request is not decided within 72 hours, it must be auto-forwarded to the IRE, do not wait for the prescriber to appeal. Document the receipt time, decision time, and any extensions accurately. For step therapy: document which step therapy requirements were applied, what clinical evidence supported them, and confirm the criteria were UM Committee-approved under 42 CFR 422.137.
Common Mistake
Starting the 72-hour clock from when the request is assigned to a reviewer rather than when it was received by the plan. CMS considers the clock to start at receipt, not at assignment. Plans that measure PA turnaround from assignment date systematically underreport their actual processing time and may be violating the 72-hour standard on a significant percentage of requests without knowing it.
Pro Tip
Set an internal 48-hour alert for standard PA requests so that operations staff have 24 hours of buffer before the 72-hour CMS deadline. Any standard PA request not decided within 48 hours of receipt should be escalated for same-day completion. This buffer ensures that genuine 72-hour violations are rare rather than routine, and that the compliance team has time to intervene before an auto-forward occurs.
Tip 5: Identify and Refer Eligible Members for Medication Therapy Management
Why It Matters
CMS requires Part D plans to offer Medication Therapy Management (MTM) services to members who meet eligibility criteria: multiple chronic conditions, taking multiple Part D covered drugs, and likely to incur annual drug costs above the threshold ($1,623 in 2025). MTM is a mandatory programme, it is not optional for plans, and it is not optional for eligible members to be offered it. Failing to identify and enrol eligible members is a CMS compliance finding. Source: AARP Policy Book: Part D MTM Requirements (2025)
What To Do
Run MTM eligibility screening quarterly at minimum, using claims data to identify members with the required number of chronic conditions, the required number of Part D drugs, and projected annual drug costs above $1,623. Enrol eligible members in the MTM programme and offer a Comprehensive Medication Review (CMR), a one-on-one consultation with a pharmacist. Document enrolment offers and outcomes. Track CMR completion rates, CMS measures MTM programme quality in part through CMR completion, which is a Star Ratings measure for Part D plans.
Common Mistake
Running the MTM eligibility screen only at the start of the plan year and not again during the year. Members who did not meet the drug cost threshold in January may meet it by March when their utilisation data is more complete. Plans that screen only annually miss members who become eligible mid-year and generate compliance findings for not offering MTM to all eligible members.
Pro Tip
MTM CMR completion is a Star Ratings measure, every completed CMR improves the plan’s score. Track CMR completion rates by outreach method and double down on the outreach channels with the highest completion rates. Members who complete a CMR are more likely to adhere to their medication regimen, which improves HEDIS medication adherence measures that are also in the Star Ratings calculation. MTM and HEDIS adherence scores are operationally linked.
Tip 6: Explain the Explanation of Benefits Correctly When Members Call About It
Why It Matters
CMS requires Part D plans to send a monthly Explanation of Benefits (EOB) to every member who filled a prescription that month. The EOB shows drugs dispensed, amounts paid by the plan, amounts paid by the member, and the member’s year-to-date out-of-pocket total toward the $2,000 cap. EOB calls are a high-volume contact reason for Part D member services, members who do not understand their EOB call to dispute charges, file complaints, or disenrol. Giving a wrong explanation of the EOB generates a new compliance problem on top of the original confusion.
What To Do
Know the EOB fields: drug name, date dispensed, pharmacy, amount billed, amount paid by plan, amount paid by member (deductible, copay, or coinsurance), and year-to-date out-of-pocket total. When a member calls about a charge on their EOB, pull their specific EOB record and walk through the charge with them line by line using those fields. Explain where they are in the benefit structure (deductible phase, coverage phase, or past the $2,000 cap). If the member believes a charge is wrong, escalate to a billing review, do not dismiss the concern or ask them to wait for next month’s EOB.
Common Mistake
Telling a member their EOB year-to-date total shows how much they have left before they reach the cap. It does not, the YTD total shows how much they have spent toward the cap, not how much remains. A member who has spent $1,800 toward the $2,000 cap has $200 remaining, not $1,800 remaining. This distinction is a common source of member confusion and plan staff error when explaining the EOB.
Pro Tip
Build a simple EOB explanation script that converts the YTD total into a “remaining” figure for the member: “Your EOB shows you have paid $X toward your $2,000 limit this year. You have $Y remaining before you reach the cap and pay $0 for the rest of the year.” Members who understand exactly where they are relative to the cap are more likely to continue filling their prescriptions, which improves medication adherence and Star Ratings simultaneously.
Tip 7: Communicate Formulary Changes to Members Accurately and on Time
Why It Matters
CMS requires Part D plans to notify affected members at least 60 days before a mid-year formulary change that removes a drug from the formulary or moves it to a higher cost-sharing tier. Without this notice, a member whose drug is removed from the formulary arrives at the pharmacy expecting to pay their usual copay and finds the drug is no longer covered. That generates a complaint, a grievance, and potential CMS compliance finding, all from a notification failure, not a coverage decision. Mid-year formulary changes must be managed operationally, not just communicated.
What To Do
When a mid-year formulary change affects an enrolled member’s current drug: send written notice at least 60 days before the change takes effect; include information about formulary alternatives at the same or lower tier; provide instructions for requesting a formulary exception if the member wants to continue the affected drug; and note that the member may be eligible for a Special Enrollment Period to switch plans. The Annual Notice of Change (ANOC) handles annual formulary changes for the following plan year, mid-year changes require separate timely notice to each affected member.
Common Mistake
Assuming the ANOC covers mid-year formulary changes. The ANOC notifies members of changes for the upcoming plan year and must be sent by September 30. A drug that is removed from the formulary in June has no ANOC coverage, it requires a separate 60-day advance notice to every member who is currently using that drug. Missing this notice is a CMS compliance violation regardless of whether the ANOC was sent on time.
Pro Tip
When a formulary change is approved, run a query immediately to identify every enrolled member currently using the affected drug based on recent claims. Generate the notice list before any other step. Plans that identify affected members within 24 hours of a formulary change decision have 60-plus days to send compliant notices and arrange transitions. Plans that identify affected members a week before the effective date are already non-compliant on the 60-day notice requirement.
Pre-Task Checklist: Part D Administration Daily Readiness
Member Interactions
LIS status verified before any drug cost is quoted
Year-to-date OOP total pulled from member record before discussing cap
M3P option offered to members with high-cost drug inquiries
EOB explanation uses “spent” and “remaining” language clearly
PA and UM Processing
PA clock starts at receipt timestamp, not assignment date
48-hour alert queue checked and escalated before 72-hour deadline
Transition supply eligibility confirmed for new member drug requests
LTC residents flagged separately for ongoing transition supply (no 90-day limit)
Programme Compliance
MTM eligibility queue reviewed quarterly for newly eligible members
Formulary change notice list generated within 24 hours of approval decision
60-day advance notice sent for mid-year drug removal or tier changes
CMR completion rates tracked monthly against Star Ratings MTM measure
Key Takeaways
LIS status and the $2,000 cap are the two things every Part D staff member must check before any cost conversation
Every Part D cost-sharing conversation requires two lookups before any number is said out loud: the member’s LIS status (which can reduce their costs to near zero) and their year-to-date out-of-pocket total (which determines how far they are from the $2,000 cap). A staff member who gives a cost figure without these two data points has a roughly one-in-five chance of quoting the wrong number due to LIS status alone, before accounting for where the member is in the benefit phase.
PA clock starts at receipt, transition policy differs for LTC, and formulary change notice must precede the change by 60 days, all three are common audit findings
Three Part D operational rules that plan staff routinely get wrong: the prior authorisation clock starts at receipt (not assignment), the transition policy for LTC residents is ongoing (not 90 days), and mid-year formulary changes require 60-day advance notice to affected members (the ANOC does not cover mid-year changes). All three generate CMS audit findings when violated, and all three are preventable with clear operational standards and system configuration that enforces the correct starting point for each process.
MTM completion and medication adherence are operationally linked to Star Ratings, Part D administration quality has a direct financial consequence
MTM Comprehensive Medication Review completion is a Star Ratings measure. Medication adherence for diabetes, hypertension, and cholesterol drugs are triple-weighted Star Ratings measures. Both are driven by Part D operational decisions: whether eligible members are identified and enrolled in MTM, whether PA processing delays block medication access, whether formulary change notices reach members before their drug is removed. The plan’s Star Rating is a downstream consequence of how well Part D is administered day to day, not an abstract quality metric decided elsewhere.
Frequently Asked Questions
What is the Medicare Part D out-of-pocket cap in 2025 and what counts toward it?
The Part D out-of-pocket cap is $2,000 in 2025 under the Inflation Reduction Act. Amounts that count toward the cap: the annual deductible, copayments, and coinsurance for covered Part D drugs, including drugs obtained through formulary exceptions. Amounts that do not count: payments for drugs not covered by the Part D plan. Once a member reaches $2,000 in annual out-of-pocket costs for covered drugs, they pay $0 in cost-sharing for the rest of the calendar year. The cap rises to $2,100 in 2026 and will be adjusted annually for drug cost inflation going forward. Source: Patient Advocate Foundation: Part D Cap (2025)
What is the Medicare Prescription Payment Plan (M3P) and who should be offered it?
The Medicare Prescription Payment Plan (M3P), introduced in 2025, allows Part D enrollees to spread their out-of-pocket drug costs across monthly instalments throughout the year rather than paying the full amount at the pharmacy counter when the drug is dispensed. A member who would otherwise pay $2,000 in January for a specialty drug can instead spread that payment across the remaining months of the year. M3P is particularly valuable for members with high-cost specialty drugs. Plan staff should offer information about M3P to any member who asks about drug costs that are high relative to their monthly budget. Source: CMS: CY2026 Part D Redesign Program Instructions
How does the Part D transition policy work for new enrollees versus long-term care residents?
For new enrollees in retail settings, the transition policy requires a temporary 30-day drug supply for non-formulary drugs during the first 90 days of coverage, with a written notice sent within 3 business days explaining that the drug is not on the formulary and describing the member’s options. For long-term care residents, the transition protections are stronger: CMS requires that LTC residents be provided transition supplies throughout their entire stay in the facility, the 90-day window does not apply to LTC residents. Denying a transition supply to a LTC resident after 90 days is a compliance violation. Both settings require documentation of transition fills and notices for CMS audit purposes.
What are the Part D prior authorisation decision timeframes?
CMS requires standard Part D coverage determination decisions within 72 hours of receipt of the request. Expedited coverage determination requests, where a prescribing physician certifies that applying the standard timeframe would seriously jeopardise the member’s life, health, or ability to regain maximum function, must be decided within 24 hours. The clock starts at receipt of the request, not when it is assigned to a reviewer or when clinical information is received. If a standard request is not decided within 72 hours, it must be automatically forwarded to the Independent Review Entity (IRE). Missing the timeframe generates an auto-forward and a CMS compliance finding.
Who is eligible for Medicare Part D Medication Therapy Management in 2025?
Under CMS requirements, Part D MTM eligibility in 2025 requires: the member has multiple chronic conditions (at least 2 to 3, depending on plan criteria); the member is taking multiple Part D covered medications (at least 2 to 8, depending on plan criteria); and the member is likely to incur annual Part D drug costs above $1,623 (the 2025 MTM cost threshold, updated annually). Plans set their specific criteria within these CMS guidelines. Eligible members must be offered enrolment in the MTM programme and a Comprehensive Medication Review, refusal of an offer must be documented. Failure to offer MTM to all eligible members is a CMS compliance finding. Source: AARP Policy Book: Part D MTM (2025)
When must a Part D plan send advance notice of a formulary change?
For mid-year formulary changes that remove a drug from the formulary or move it to a higher cost-sharing tier, CMS requires written notice to affected members at least 60 days before the change takes effect. The notice must explain what is changing, when it takes effect, what formulary alternatives are available, how to request a formulary exception, and that the member may be eligible for a Special Enrollment Period to switch plans. The Annual Notice of Change (ANOC) sent by September 30 covers plan-year changes for the following year, it does not cover mid-year changes. Any mid-year formulary change affecting a current member requires a separate, timely, compliant notice.
How does Part D administration affect Star Ratings?
Part D plan performance is measured through the Part D Star Ratings, which are included in the overall MA-PD Star Rating for combined plans. Key Part D Star Ratings measures include: MTM Comprehensive Medication Review completion rate; medication adherence for diabetes medications, hypertension medications, and cholesterol medications (all triple-weighted); drug plan customer service; appeals auto-forward rate; and pricing accuracy. Plan operations drive each of these: MTM completion depends on member identification and outreach; medication adherence depends on PA processing speed and formulary access; appeals auto-forward rate depends on PA decision timelines; pricing accuracy depends on LIS application and cost-sharing configuration. Every Part D administration tip in this article connects directly to a Star Ratings measure.
Sources
Government Sources
- CMS: Final CY2026 Part D Redesign Program Instructions (March 2026): source for the $2,100 OOP threshold for 2026, the M3P Medicare Prescription Payment Plan implementation guidance, and the successor regulation exception to the IRA formulary inclusion requirements.
- Congressional Research Service: Medicare Part D Prescription Drug Benefit (2025): source for the 14.2 million LIS beneficiaries in 2023, the overall Part D programme structure, and the federal legislative history of the Inflation Reduction Act changes taking effect 2023 to 2026.
Policy and Industry Sources
- Patient Advocate Foundation: Understanding the Medicare Part D Cap (October 2025): source for the $2,000 OOP cap structure, what counts and does not count toward the cap, the role of formulary exceptions in cap calculation, and the 2026 increase to $2,100.
- AARP Policy Book: Medicare Part D Prescription Drugs in Medicare (2025): source for the 50%+ utilisation management figure (PDPs and MA-PDs applying PA, step therapy, or quantity limits to more than half of formulary drugs in 2024), and the MTM annual cost threshold of $1,623 in 2025.
- GoodRx: Medicare Part D Out-of-Pocket Limit (December 2025): source for the contrast between the 2024 $8,000 threshold and the 2025 $2,000 cap, and the practical pharmacy-level implications of the cap for high-cost drug members.
Related VelSafe Articles
Guides
Medicare Advantage Quality and Utilization Management Guide
The full QM and UM operational guide, covering how MTM CMR completion, medication adherence measures, and prior authorisation UM Committee governance connect to Star Ratings performance.
Tips
7 Medicare Advantage Member Services Tips
The companion tips article for the MA side, CMS call centre thresholds, grievance triage, interpreter access, and documentation standards that parallel the Part D administration requirements covered here.
Insights
Medicare Broker Agent Training: What the Data Shows
Evidence analysis of the enrollment channel, covering how agent accuracy failures at the point of Part D enrollment create the LIS misapplication and formulary misunderstanding problems that Part D administrators have to resolve on the back end.
MEDICARE PART D TIPS LIBRARY
More Medicare Part D Operational Tips
Explore VelSafe’s Medicare Part D tips library for practical, compliance-focused guidance on formulary management, LIS administration, prior authorisation, MTM, and member communication.
Explore All Tips
